↑ 薬物リストへ　← 戻る

Vb119    (DrugBank: -)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
222一次性ネフローゼ症候群1

222. 一次性ネフローゼ症候群　［臨床試験数：234，薬物数：241（DrugBank：78），標的遺伝子数：59，標的パスウェイ数：185］
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 234 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04652570
(ClinicalTrials.gov)		February 202123/11/2020Efficacy and Safety of VB119 in Subjects With Membranous NephropathyA Phase 1b/2a Study of VB119 in Adult Subjects With Primary Membranous NephropathyMembranous NephropathyDrug: VB119ValenzaBio, Inc.NULLNot yet recruiting18 YearsN/AAll30Phase 1;Phase 2NULL